SCHEMBL40450

SCHEMBL40450

Nc1cnc(Cl)nc1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23114264 0.72 MEN1 (0.43)
SCHEMBL8098714 0.72 NPC1 (0.35)
SCHEMBL149636 0.72
SCHEMBL2495212 0.72
SCHEMBL4718559 0.69 APP (0.58)
SCHEMBL9593 0.67
SCHEMBL3712918 0.67
SCHEMBL904190 0.67 KDM4E (0.37)
SCHEMBL14656039 0.67
SCHEMBL9779757 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 568 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119350937-A Double-component aerosol spray paint and preparation method thereof 广东豪之盛新材料有限公司 2025-01-24 CN claimed
CN-102127081-B Preparation method of adenine WUHAN INST TECHNOLOGY 2012-11-28 CN claimed
CN-102127081-A Preparation method of adenine WUHAN INST TECHNOLOGY 2011-07-20 CN claimed
CN-101219997-B Synthesis of 2-chlorine-5- amido pyrimidine Suzhou bohong chemical technology co ltd 2011-04-20 CN claimed
EP-1451160-B1 PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN ICAGEN INC (US) 2010-01-13 EP claimed
CN-101219997-A Synthesis of 2-chlorine-5- amido pyrimidine SUZHOU YIELD PHARMACEUTICAL R (CN) 2008-07-16 CN claimed
WO-2026041663-A1 P2X7 RECEPTOR ANTAGONISTS BREYE THERAPEUTICS APS (DK) 2026-02-26 WO disclosed
EP-4699607-A2 N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS Vertex Pharmaceuticals Incorporated (US) 2026-02-25 EP disclosed
EP-4695236-A1 SUBSTITUTED PHENYL-PIPERAZINYL BASED MODULATORS FOR THE TREATMENT OF DISEASE Soley Therapeutics, Inc. (US) 2026-02-18 EP disclosed
EP-4334298-B1 UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER SCORPION THERAPEUTICS INC (US) 2026-02-18 EP disclosed
EP-4680612-A1 CHEMICAL COMPOUNDS AN2 Therapeutics, Inc. (US) 2026-01-21 EP disclosed
US-12528827-B2 Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2026-01-20 US disclosed
US-20250353836-A1 N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMA (US) 2025-11-20 US disclosed
EP-1483259-A1 PYRIMIDINES AS NOVEL OPENERS OF POTASSIUM ION CHANNELS Icagen, Inc. (US) 2004-12-08 EP disclosed
CN-1501927-A Trifluoromethylpurines as phosphodiesterase 4 inhibitors 记忆药物公司 2004-06-02 CN disclosed
US-20030181465-A1 Pyrimidines as novel openers of potassium ion channels ICAGEN, INC. 2003-09-25 US disclosed
WO-2003068767-A1 PYRIMIDINES AS NOVEL OPENERS OF POTASSIUM ION CHANNELS ICAGEN, INC. (US) 2003-08-21 WO disclosed
CN-1226166-A Formulations and methods for treating congestive heart failure ELI LITTY AND COMPANY (US) 1999-08-18 CN disclosed
CN-1194140-A Medicine LILLY CO ELI (US) 1998-09-30 CN disclosed
CN-1145226-A Method for treating substance abuse withdrawal LILLY CO ELI (US) 1997-03-19 CN disclosed